Pharmafile Logo

Multi-level Segmentation Solution

September 6, 2017 | Case study, Quantitative, Segmentation 

Our client has an established product for multiple indications. They wanted to create a HCP segmentation typing tool which could be implemented in-field to help classify physicians across two different therapeutic areas. There was rationale to suggest that because the two therapeutic areas are pathologically different, then two separate typing tools would be required. However, it was also argued that a one segment solution would be most suitable as physicians fundamentally have the same attitudes, irrespective of the disease they are treating. Additionally, our client would be able to implement a single segmentation tool into its core business much more efficiently than two separate tools. The challenge was to therefore decide whether a one tool or two tool solution would be most suitable.

Find out more: https://www.researchpartnership.com/news/2017/08/multi-level-segmentation-solution/

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Summer Intern experience at Research Partnership

We look for bright and inquisitive people who want to learn in a company that's pushing the boundaries of pharmaceutical market research

Double win at Communiqué 2016: Pegasus scoops awards for Consultancy of the Year (for the second time!) and Excellence in Media Relations

Pegasus, an Ashfield company, part of UDG Healthcare plc, is delighted to have won the prestigious Consultancy of the Year award at the 2016 Communiqué Awards in London. The judges...

Beyond Andrology: Trends in Men’s Health in Emerging Markets

Published in eyeforpharma July 2016 by Rachel Howard

Pharma & life sciences division growth allows Pegasus to fill three new senior positions

Pegasus has expanded its pharma & life sciences senior team by appointing a new Associate Director and promoting two members of the existing team to Account Directors.

Infographic: HIV Market Snapshot

Our latest HIV infographic, taken from data collected from syndicated tracking study Therapy Watch, reveals that more than 3 in 5 naive or switch patients are currently treated with a STR (single...

Infographic: The vaccine opportunity in Asia

As predicted, the vaccine market in emerging and developing countries has continued to expand. While the global vaccine market is expected to grow at around 12% annually over the next...

Webinar: What next for biosimilars?

Tuesday 19th July 15:00 BST/10:00 EDT/16:00 CEST

Understanding the Patient Journey

The patient journey is changing. Patients are now much more educated and engaged. They have access to information and want to be involved in decisions around their treatment programme.  Technology...

Case Study: Oncology diagnostic biomarker landscaping study

The challenge:Our client needed to understand moleculardiagnostic testing growth opportunities for a new biomarker in oncology. They wanted to understand the current market landscape, identify potential leverage points that would maximise use of the biomarker...

Research Partnership publishes 2016 Living with RA reports

Research Partnership has published new Living with rheumatoid arthritis (RA) EU and US market reports for 2016.